Trials / Completed
CompletedNCT04664023
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 and Its Resolution
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 130 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Prospective study to describe the immunological, metabolic and serologic profile in the acute and post acute phases of Coronavirus disease (COVID-19)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection. | 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis |
| PROCEDURE | Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers | 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis |
Timeline
- Start date
- 2020-12-09
- Primary completion
- 2023-06-19
- Completion
- 2023-06-19
- First posted
- 2020-12-11
- Last updated
- 2023-06-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04664023. Inclusion in this directory is not an endorsement.